Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $6.25.

ESPR has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Friday, April 25th. JMP Securities restated a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. The Goldman Sachs Group cut their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. Finally, Needham & Company LLC reduced their price target on Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th.

Esperion Therapeutics Trading Up 1.7%

Shares of NASDAQ:ESPR opened at $1.22 on Wednesday. The company has a market capitalization of $241.80 million, a PE ratio of -1.91 and a beta of 0.67. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.94. The business’s fifty day simple moving average is $0.95 and its 200-day simple moving average is $1.68.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The business had revenue of $65.00 million during the quarter, compared to the consensus estimate of $54.97 million. Research analysts predict that Esperion Therapeutics will post -0.29 EPS for the current year.

Institutional Trading of Esperion Therapeutics

Several large investors have recently bought and sold shares of ESPR. J.W. Cole Advisors Inc. acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth $66,000. Sigma Planning Corp raised its stake in Esperion Therapeutics by 1,455.8% in the 4th quarter. Sigma Planning Corp now owns 190,441 shares of the biopharmaceutical company’s stock worth $419,000 after acquiring an additional 178,200 shares during the last quarter. Summit Wealth Group LLC lifted its position in Esperion Therapeutics by 292.5% during the 4th quarter. Summit Wealth Group LLC now owns 157,000 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 117,000 shares during the period. Victory Capital Management Inc. lifted its position in Esperion Therapeutics by 602.8% during the 4th quarter. Victory Capital Management Inc. now owns 173,083 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 148,456 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Esperion Therapeutics during the 4th quarter valued at about $98,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.